The FDA has approved Zynyz as a first-line treatment in combination with chemo and as a single-agent following progression in ...

The report provides extensive insights into over 180 companies and 200 drugs in the PD-1 and PD-L1 inhibitors market. This comprehensive resource focuses on treatment assessments by product type, ...

High-risk NMIBC is characterised by poor prognosis, with half of patients recurring despite effective treatment with the ...

Pfizer has linked its PD-1 inhibitor to a 32% reduction in the risk of disease-related events in a phase 3 bladder cancer trial ... could become the first PD-1 drug approved in the indication.

Previously, the drug has been approved in China ... anlotinib in first-line liver cancer is under review with Chinese authorities. About 10 PD-1/L1 inhibitors have reached the U.S. market before ...

The FDA has approved Akeso’s penpulimab-kcqx, a PD-1 monoclonal antibody ... challenge global standards of care and unlocking the full potential of our pipeline for cancer patients everywhere." The ...

The intriguing VEGFxPD-1 bispecific antibody space gained oomph with phase III results disclosed April 23 by Akeso ...

The FDA has dropped a bomb on Eli Lilly's marketing application for cancer immunotherapy sintilimab ... clinical results filed in support of the PD-1 inhibitor do not meet the criteria for foreign ...

The selloff came close on the heels of the FDA approval of Akeso’s (OTCPK:AKESF) PD-1 inhibitor penpulimab-kcqx, in combination with chemotherapy as a first-line option for adults with a certain ...

CS2009 is a promising trispecific antibody targeting PD-1, VEGFA, and CTLA-4, which demonstrates broad clinical application prospects for solid tumors with the great potential to become the ...

Merck & Co/MSD has won approval in the US for PD-1 inhibitor Keytruda ... form of liver cancer, opening up another front in its rivalry with Bristol-Myers Squibb. The FDA approval is based on ...